Cary B. Cole, President, Chief Executive Officer & Board Member - Mr. Cole joined Broncus Technologies in June 2001 as Vice President of Marketing. In November 2002 his responsibilities expanded to include leadership of the Company's emphysema program. Following the spin-off of the Company's asthma program in September 2003, Mr. Cole was promoted to President & Chief Operating Officer. On April 1, 2004, Mr. Cole was promoted to President & Chief Executive Officer. Prior to joining Broncus, Mr. Cole was Co-founder and Vice President of Marketing and Sales at CompuRAD, Inc. (NASDAQ:COMD) where his contributions resulted in the launch of multiple successful products, a rapid and consistent sales ramp and a successful H&Q-led IPO. Following the IPO, CompuRAD merged with Lumisys, Inc. (NASDAQ:LUMI), which was subsequently acquired by Kodak Health Imaging. At Lumisys, Mr. Cole was Vice President of Marketing, where he managed global marketing operations and direct sales. Mr. Cole is a graduate of the University of Arizona (B.S. in Business Administration).
Broncus is devoted to improving the lives of people with lung diseases by developing novel medical devices for Interventional Bronchoscopy, a new sub-specialty of pulmonologists and thoracic surgeons who perform diagnostic and therapeutic procedures through a bronchoscope.
Emphysema is one of the battlegrounds where we believe we can make a difference with technology. Broncus is investigating the Exhale® Drug-Eluting Stent for the airway bypass procedure -- a minimally-invasive treatment being studied to relieve emphysema symptoms. Broncus is currently enrolling a randomized, pivotal, phase III, IDE study, called the EASE Trial, in patients with homogeneous emphysema.
